Last reviewed · How we verify

6MPindividualized — Competitive Intelligence Brief

6MPindividualized (6MPindividualized) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Purine analog, immunosuppressant. Area: Oncology, Immunology.

phase 3 Purine analog, immunosuppressant Purine metabolism pathway (HGPRT, TPMT) Oncology, Immunology Small molecule Live · refreshed every 30 min

Target snapshot

6MPindividualized (6MPindividualized) — Rigshospitalet, Denmark. 6MP (6-mercaptopurine) is a purine analog that inhibits nucleotide synthesis and suppresses immune cell proliferation.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
6MPindividualized TARGET 6MPindividualized Rigshospitalet, Denmark phase 3 Purine analog, immunosuppressant Purine metabolism pathway (HGPRT, TPMT)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Purine analog, immunosuppressant class)

  1. Rigshospitalet, Denmark · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). 6MPindividualized — Competitive Intelligence Brief. https://druglandscape.com/ci/6mpindividualized. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: